clinical trial · NCT04221230
Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo
Major Depressive DisorderNMRA-335140Placebo
brief summary
A proof of concept (POC) study evaluating the impact of NMRA-335140 (BTRX-335140) relative to placebo on symptoms of major depressive disorder (MDD) in adult participants with MDD and symptoms of anhedonia and anxiety following 8 weeks of double-blind treatment as assessed by the HAMD-17 Scale.
started
Jan 3, 2020
primary completion
Apr 8, 2022
completion
Jun 23, 2022
last updated
May 29, 2025
official title
A Phase 2a, Randomized, Double-blind, Placebo-controlled Proof of Concept Study to Evaluate the Effects of Oral BTRX-335140 (NMRA-335140) Versus Placebo in Subjects With Major Depressive Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol